Atherosclerosis and Alzheimer - Diseases with a common cause? Inflammation, oxysterols, vasculature

BMC Geriatrics

Volumn 14, Issue 1, 2014, Pages

  Lathe, Richard ^a,b,c   Sapronova, Alexandra ^a,b,d   Kotelevtsev, Yuri ^a,b,e,f  

^a PUSHCHINO STATE UNIVERSITY   (Russian Federation)

^b SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^c Pieta Research   (United Kingdom)

^d KOL TSOV INSTITUTE OF DEVELOPMENTAL BIOLOGY   (Russian Federation)

^e SKOLKOVO INSTITUTE OF SCIENCE AND TECHNOLOGY   (Russian Federation)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

25 hydroxycholesterol; Alzheimer; APOE; Atherosclerosis; Cholesterol; Infection; Inflammation

Indexed keywords

25 HYDROXYCHOLESTEROL; 25-HYDROXYCHOLESTEROL; AMYLOID BETA PROTEIN; AUTACOID; CHOLESTEROL DERIVATIVE;

AGING; ALZHEIMER DISEASE; ANIMAL; ATHEROSCLEROSIS; BLOOD; BRAIN; HUMAN; INFLAMMATION; METABOLISM; PATHOLOGY; REVIEW; VASCULARIZATION;

AGING; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ATHEROSCLEROSIS; BRAIN; HUMANS; HYDROXYCHOLESTEROLS; INFLAMMATION; INFLAMMATION MEDIATORS;

EID: 84899097056     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-14-36     Document Type: Review

References (364)

1. Ill or just old? Towards a conceptual framework of the relation between ageing and disease. Izaks GJ, Westendorp RG, BMC Geriatr 2003 3 7 10.1186/1471-2318-3-7 14683526
2. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, Carnethon MR, Dai S, de Simone G, Ford ES, Fox CS, Fullerton HJ, Gillespie C, Greenlund KJ, Hailpern SM, Heit JA, Ho PM, Howard VJ, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Makuc DM, Marcus GM, Marelli A, Matchar DB, McDermott MM, Meigs JB, Moy CS, et al. Circulation 2011 123 18 e209 10.1161/CIR.0b013e3182009701 21160056
3. Atherosclerotic cardiovascular disease screening in adults: American College Of Preventive Medicine position statement on preventive practice. Lim LS, Haq N, Mahmood S, Hoeksema L, Am J Prev Med 2011 40 381 10 21335273
4. Epidemiology of Alzheimer disease. Mayeux R, Stern Y, Cold Spring Harb Perspect Med 2012 2 006239 22908189
5. Epidemiology of Alzheimer's disease and other forms of dementia in China, 1990-2010: a systematic review and analysis. Chan KY, Wang W, Wu JJ, Liu L, Theodoratou E, Car J, Middleton L, Russ TC, Deary IJ, Campbell H, Wang W, Rudan I, Lancet 2013 381 2016 2023 10.1016/S0140-6736(13)60221-4 23746902
6. Atherosclerosis. Lusis AJ, Nature 2000 407 233 241 10.1038/35025203 11001066
7. Neurovascular regulation in the normal brain and in Alzheimer's disease. Iadecola C, Nat Rev Neurosci 2004 5 347 360 10.1038/nrn1387 15100718
8. Kinetics of cerebral amyloid angiopathy progression in a transgenic mouse model of Alzheimer disease. Robbins EM, Betensky RA, Domnitz SB, Purcell SM, Garcia-Alloza M, Greenberg C, Rebeck GW, Hyman BT, Greenberg SM, Frosch MP, Bacskai BJ, J Neurosci 2006 26 365 371 10.1523/JNEUROSCI.3854-05.2006 16407531
9. Classic beta-amyloid deposits cluster around large diameter blood vessels rather than capillaries in sporadic Alzheimer's disease. Armstrong RA, Curr Neurovasc Res 2006 3 289 294 10.2174/156720206778792948 17109624
10. A spatial pattern analysis of beta-amyloid (Abeta) deposition in the temporal lobe in Alzheimer's disease. Armstrong RA, Folia Neuropathol 2010 48 67 74 20602287
11. Alzheimer's disease and angiogenesis. Vagnucci AH Jr, Li WW, Lancet 2003 361 605 608 10.1016/S0140-6736(03)12521-4 12598159
12. The diagnosis of dementia with single photon emission computed tomography. Jagust WJ, Budinger TF, Reed BR, Arch Neurol 1987 44 258 262 10.1001/archneur.1987.00520150014011 3493756
13. Cerebral perfusion imaging in Alzheimer's disease. Use of single photon emission computed tomography and iofetamine hydrochloride I 123. Johnson KA, Mueller ST, Walshe TM, English RJ, Holman BL, Arch Neurol 1987 44 165 168 10.1001/archneur.1987.00520140035014 3492992
14. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Niwa K, Kazama K, Younkin SG, Carlson GA, Iadecola C, Neurobiol Dis 2002 9 61 68 10.1006/nbdi.2001.0460 11848685
15. Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer's disease. Roher AE, Esh C, Kokjohn TA, Kalback W, Luehrs DC, Seward JD, Sue LI, Beach TG, Arterioscler Thromb Vasc Biol 2003 23 2055 2062 10.1161/01.ATV.0000095973.42032.44 14512367
16. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Hofman A, Ott A, Breteler MM, Bots ML, Slooter AJ, van HF, van Duijn CN, Van BC, Grobbee DE, Lancet 1997 349 151 154 10.1016/S0140-6736(96)09328-2 9111537
17. Cardiovascular factors in Alzheimer's disease. Stewart R, J Neurol Neurosurg Psychiatry 1998 65 143 147 10.1136/jnnp.65.2.143 9703160
18. Cerebrovascular disease and dementia. Knopman DS, Br J Radiol 2007 80 Spec No 2 121 S127 18445742
19. Carotid atherosclerosis and prospective risk of dementia. Wendell CR, Waldstein SR, Ferrucci L, O'Brien RJ, Strait JB, Zonderman AB, Stroke 2012 43 3319 3324 10.1161/STROKEAHA.112.672527 23103489
20. Circle of Willis atherosclerosis: association with Alzheimer's disease, neuritic plaques and neurofibrillary tangles. Beach TG, Wilson JR, Sue LI, Newell A, Poston M, Cisneros R, Pandya Y, Esh C, Connor DJ, Sabbagh M, Walker DG, Roher AE, Acta Neuropathol 2007 113 13 21 17021755
21. Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Dolan H, Crain B, Troncoso J, Resnick SM, Zonderman AB, Obrien RJ, Ann Neurol 2010 68 231 240 20695015
22. Cerebral amyloid angiopathy in the brains of patients with Alzheimer's disease: the CERAD experience, Part XV. Ellis RJ, Olichney JM, Thal LJ, Mirra SS, Morris JC, Beekly D, Heyman A, Neurology 1996 46 1592 1596 10.1212/WNL.46.6.1592 8649554
23. The role of small vessel disease in development of Alzheimer's disease. Grau-Slevin M, Arboix A, Gaffney J, Slevin M, Neural Reg Res 2010 5 310 320
24. Overlap between pathology of Alzheimer disease and vascular dementia. Kalaria RN, Ballard C, Alzheimer Dis Assoc Disord 1999 13 Suppl 3 115 S123 10609690
25. Cerebral blood flow in Alzheimer's disease. Roher AE, Debbins JP, Malek-Ahmadi M, Chen K, Pipe JG, Maze S, Belden C, Maarouf CL, Thiyyagura P, Mo H, Hunter JM, Kokjohn TA, Walker DG, Kruchowsky JC, Belohlavek M, Sabbagh MN, Beach TG, Vasc Health Risk Manag 2012 8 599 611 23109807
26. Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Zambon D, Quintana M, Mata P, Alonso R, Benavent J, Cruz-Sanchez F, Gich J, Pocovi M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA, Am J Med 2010 123 267 274 10.1016/j.amjmed.2009.08.015 20193836
27. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE, Nat Genet 2007 39 17 23 10.1038/ng1934 17192785
28. CADgene: a comprehensive database for coronary artery disease genes. Liu H, Liu W, Liao Y, Cheng L, Liu Q, Ren X, Shi L, Tu X, Wang QK, Guo AY, Nucleic Acids Res 2011 39 991 D996 10.1093/nar/gkq1106 21045063
29. Genetics of peripheral artery disease. Leeper NJ, Kullo IJ, Cooke JP, Circulation 2012 125 3220 3228 10.1161/CIRCULATIONAHA.111.033878 22733336
30. The genetics of Alzheimer disease. Tanzi RE, Cold Spring Harb Perspect Med 2012 2 006296 23028126
31. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman HH, Fornazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, et al. Arch Neurol 2008 65 45 53 17998437
32. Comprehensive search for Alzheimer disease susceptibility loci in the APOE region. Jun G, Vardarajan BN, Buros J, Yu CE, Hawk MV, Dombroski BA, Crane PK, Larson EB, Mayeux R, Haines JL, Lunetta KL, Pericak-Vance MA, Schellenberg GD, Farrer LA, Arch Neurol 2012 69 1270 1279 10.1001/archneurol.2012.2052 22869155
33. Genome-wide association study identifies a single major locus contributing to survival into old age; the APOE locus revisited. Deelen J, Beekman M, Uh HW, Helmer Q, Kuningas M, Christiansen L, Kremer D, van der Breggen R, Suchiman HE, Lakenberg N, van den Akker EB, Passtoors WM, Tiemeier H, van HD, de Craen AJ, Rivadeneira F, de Geus EJ, Perola M, van der Ouderaa FJ, Gunn DA, Boomsma DI, Uitterlinden AG, Christensen K, van Duijn CM, Heijmans BT, Houwing-Duistermaat JJ, Westendorp RG, Slagboom PE, Aging Cell 2011 10 686 698 10.1111/j.1474-9726.2011.00705.x 21418511
34. Genetic variants in LPL, OASL and TOMM40/APOE-C1-C2-C4 genes are associated with multiple cardiovascular-related traits. Middelberg RP, Ferreira MA, Henders AK, Heath AC, Madden PA, Montgomery GW, Martin NG, Whitfield JB, BMC Med Genet 2011 12 123 10.1186/1471-2350-12-123 21943158
35. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, Reiman EM, Pharmacogenomics J 2010 10 375 384 10.1038/tpj.2009.69 20029386
36. Association and expression analyses with single-nucleotide polymorphisms in TOMM40 in Alzheimer disease. Cruchaga C, Nowotny P, Kauwe JS, Ridge PG, Mayo K, Bertelsen S, Hinrichs A, Fagan AM, Holtzman DM, Morris JC, Goate AM, Arch Neurol 2011 68 1013 1019 10.1001/archneurol.2011.155 21825236
37. TOMM40 rs10524523 polymorphism's role in late-onset Alzheimer's disease and in longevity. Maruszak A, Peplonska B, Safranow K, Chodakowska-Zebrowska M, Barcikowska M, Zekanowski C, J Alzheimers Dis 2012 28 309 322 22008263
38. Cryptogenic organizing pneumonia in Tomm5-/- mice. Vogel P, Read RW, Rehg JE, Hansen GM, Vet Pathol 2013 50 65 75 10.1177/0300985812450723 22688586
39. Functional analysis of APOE locus genetic variation implicates regional enhancers in the regulation of both TOMM40 and APOE. Bekris LM, Lutz F, Yu CE, J Hum Genet 2012 57 18 25 10.1038/jhg.2011.123 22089642
40. Promising genetic biomarkers of preclinical Alzheimer's disease: the influence of APOE and TOMM40 on brain integrity. Ferencz B, Karlsson S, Kalpouzos G, Int J Alzheimers Dis 2012 2012 421452 22550605
41. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. Oram JF, Yokoyama S, J Lipid Res 1996 37 2473 2491 9017501
42. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Grundy SM, Circulation 2002 106 2526 2529 10.1161/01.CIR.0000038419.53000.D6 12427645
43. Reverse cholesterol transport and cholesterol efflux in atherosclerosis. Ohashi R, Mu H, Wang X, Yao Q, Chen C, QJM 2005 98 845 856 10.1093/qjmed/hci136 16258026
44. Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport. Rosenson RS, Brewer HB Jr, Davidson WS, Fayad ZA, Fuster V, Goldstein J, Hellerstein M, Jiang XC, Phillips MC, Rader DJ, Remaley AT, Rothblat GH, Tall AR, Yvan-Charvet L, Circulation 2012 125 1905 1919 10.1161/CIRCULATIONAHA.111.066589 22508840
45. High density lipoprotein structure-function and role in reverse cholesterol transport. Lund-Katz S, Phillips MC, Subcell Biochem 2010 51 183 227 10.1007/978-90-481-8622-8-7 20213545
46. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. Mahley RW, Ji ZS, J Lipid Res 1999 40 1 16 9869645
47. Apolipoprotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Corbo RM, Scacchi R, Ann Hum Genet 1999 63 301 310 10.1046/j.1469-1809.1999.6340301.x 10738542
48. Apolipoprotein E: far more than a lipid transport protein. Mahley RW, Rall SC Jr, Annu Rev Genomics Hum Genet 2000 1 507 537 10.1146/annurev.genom.1. 1.507 11701639
49. The genetics of the human APOE polymorphism. Seripa D, D'Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotto A, Rejuvenation Res 2011 14 491 500 10.1089/rej.2011.1169 21958003
50. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. Mahley RW, Weisgraber KH, Huang Y, J Lipid Res 2009 50 Suppl 183 S188 19106071
51. Apolipoprotein E4 forms a molten globule. A potential basis for its association with disease. Morrow JA, Hatters DM, Lu B, Hochtl P, Oberg KA, Rupp B, Weisgraber KH, J Biol Chem 2002 277 50380 50385 10.1074/jbc.M204898200 12393895
52. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112. Weisgraber KH, J Lipid Res 1990 31 1503 1511 2280190
53. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. Dong LM, Wilson C, Wardell MR, Simmons T, Mahley RW, Weisgraber KH, Agard DA, J Biol Chem 1994 269 22358 22365 8071364
54. Human apolipoprotein E4 domain interaction. Arginine 61 and glutamic acid 255 interact to direct the preference for very low density lipoproteins. Dong LM, Weisgraber KH, J Biol Chem 1996 271 19053 19057 10.1074/jbc.271.32.19053 8702576
55. Molecular basis for the differences in lipid and lipoprotein binding properties of human apolipoproteins E3 and E4. Nguyen D, Dhanasekaran P, Nickel M, Nakatani R, Saito H, Phillips MC, Lund-Katz S, Biochemistry 2010 49 10881 10889 10.1021/bi1017655 21114327
56. Impaired recycling of apolipoprotein E4 is associated with intracellular cholesterol accumulation. Heeren J, Grewal T, Laatsch A, Becker N, Rinninger F, Rye KA, Beisiegel U, J Biol Chem 2004 279 55483 55492 10.1074/jbc.M409324200 15485881
57. Novel action of apolipoprotein E (ApoE): ApoE isoform specifically inhibits lipid-particle-mediated cholesterol release from neurons. Gong JS, Morita SY, Kobayashi M, Handa T, Fujita SC, Yanagisawa K, Michikawa M, Mol Neurodegener 2007 2 9 10.1186/1750-1326-2-9 17504523
58. Mechanism underlying apolipoprotein E (ApoE) isoform-dependent lipid efflux from neural cells in culture. Minagawa H, Gong JS, Jung CG, Watanabe A, Lund-Katz S, Phillips MC, Saito H, Michikawa M, J Neurosci Res 2009 87 2498 2508 10.1002/jnr.22073 19326444
59. ABCA1 mediates high-affinity uptake of 25-hydroxycholesterol by membrane vesicles and rapid efflux of oxysterol by intact cells. Tam SP, Mok L, Chimini G, Vasa M, Deeley RG, Am J Physiol Cell Physiol 2006 291 490 C502 10.1152/ajpcell.00055.2006 16611739
60. Apolipoprotein E4 is deficient in inducing macrophage ABCA1 expression and stimulating the Sp1 signaling pathway. Okoro EU, Zhao Y, Guo Z, Zhou L, Lin X, Yang H, PLoS One 2012 7 44430 10.1371/journal.pone.0044430 22984509
61. Carboxyl-terminal-truncated apolipoprotein E4 causes Alzheimer's disease-like neurodegeneration and behavioral deficits in transgenic mice. Harris FM, Brecht WJ, Xu Q, Tesseur I, Kekonius L, Wyss-Coray T, Fish JD, Masliah E, Hopkins PC, Scearce-Levie K, Weisgraber KH, Mucke L, Mahley RW, Huang Y, Proc Natl Acad Sci U S A 2003 100 10966 10971 10.1073/pnas.1434398100 12939405
62. Neuron-specific apolipoprotein e4 proteolysis is associated with increased tau phosphorylation in brains of transgenic mice. Brecht WJ, Harris FM, Chang S, Tesseur I, Yu GQ, Xu Q, Dee FJ, Wyss-Coray T, Buttini M, Mucke L, Mahley RW, Huang Y, J Neurosci 2004 24 2527 2534 10.1523/JNEUROSCI.4315-03.2004 15014128
63. Lipid- and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Chang S, ran MT, Miranda RD, Balestra ME, Mahley RW, Huang Y, Proc Natl Acad Sci U S A 2005 102 18694 18699 10.1073/pnas.0508254102 16344479
64. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Mahley RW, Science 1988 240 622 630 10.1126/science.3283935 3283935
65. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Mahley RW, Huang Y, Curr Opin Lipidol 1999 10 207 217 10.1097/00041433- 199906000-00003 10431657
66. Mouse models of atherosclerosis. Breslow JL, Science 1996 272 685 688 10.1126/science.272.5262.685 8614828
67. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. Ishibashi S, Goldstein JL, Brown MS, Herz J, Burns DK, J Clin Invest 1994 93 1885 1893 10.1172/JCI117179 8182121
68. A mouse model of human familial hypercholesterolemia: markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Powell-Braxton L, Veniant M, Latvala RD, Hirano KI, Won WB, Ross J, Dybdal N, Zlot CH, Young SG, Davidson NO, Nat Med 1998 4 934 938 10.1038/nm0898-934 9701246
69. Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production. Citron M, Oltersdorf T, Haass C, McConlogue L, Hung AY, Seubert P, Vigo-Pelfrey C, Lieberburg I, Selkoe DJ, Nature 1992 360 672 674 10.1038/360672a0 1465129
70. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Sturchler-Pierrat C, Abramowski D, Duke M, Wiederhold KH, Mistl C, Rothacher S, Ledermann B, Burki K, Frey P, Paganetti PA, Waridel C, Calhoun ME, Jucker M, Probst A, Staufenbiel M, Sommer B, Proc Natl Acad Sci U S A 1997 94 13287 13292 10.1073/pnas.94.24.13287 9371838
71. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. Reaume AG, Howland DS, Trusko SP, Savage MJ, Lang DM, Greenberg BD, Siman R, Scott RW, J Biol Chem 1996 271 23380 23388 10.1074/jbc.271.38.23380 8798542
72. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. Irizarry MC, McNamara M, Fedorchak K, Hsiao K, Hyman BT, J Neuropathol Exp Neurol 1997 56 965 973 10.1097/00005072-199709000-00002 9291938
73. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Tokuda T, Calero M, Matsubara E, Vidal R, Kumar A, Permanne B, Zlokovic B, Smith JD, Ladu MJ, Rostagno A, Frangione B, Ghiso J, Biochem J 2000 348 Pt 2 359 365 10816430
74. Apolipoprotein E4 potentiates amyloid beta peptide-induced lysosomal leakage and apoptosis in neuronal cells. Ji ZS, Miranda RD, Newhouse YM, Weisgraber KH, Huang Y, Mahley RW, J Biol Chem 2002 277 21821 21828 10.1074/jbc.M112109200 11912196
75. Apolipoprotein (apo) E4 enhances amyloid beta peptide production in cultured neuronal cells: apoE structure as a potential therapeutic target. Ye S, Huang Y, Mullendorff K, Dong L, Giedt G, Meng EC, Cohen FE, Kuntz ID, Weisgraber KH, Mahley RW, Proc Natl Acad Sci U S A 2005 102 18700 18705 10.1073/pnas.0508693102 16344478
76. Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. de Meyer GR, de Cleen DM, Cooper S, Knaapen MW, Jans DM, Martinet W, Herman AG, Bult H, Kockx MM, Circ Res 2002 90 1197 1204 10.1161/01.RES.0000020017.84398.61 12065323
77. Alzheimer disease macrophages shuttle amyloid-beta from neurons to vessels, contributing to amyloid angiopathy. Zaghi J, Goldenson B, Inayathullah M, Lossinsky AS, Masoumi A, Avagyan H, Mahanian M, Bernas M, Weinand M, Rosenthal MJ, Espinosa-Jeffrey A, de VJ, Teplow DB, Fiala M, Acta Neuropathol 2009 117 111 124 10.1007/s00401-008-0481-0 19139910
78. Tissue transglutaminase colocalizes with extracellular matrix proteins in cerebral amyloid angiopathy. de Jager M, van der Wildt B, Schul E, Bol JG, van Duinen SG, Drukarch B, Wilhelmus MM, Neurobiol Aging 2013 34 1159 1169 10.1016/j.neurobiolaging.2012.10.005 23122413
79. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. Lee PH, Bang OY, Hwang EM, Lee JS, Joo US, Mook-Jung I, Huh K, J Neural Transm 2005 112 1371 1379 10.1007/s00702-004-0274-0 15682267
80. beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Thomas T, Thomas G, McLendon C, Sutton T, Mullan M, Nature 1996 380 168 171 10.1038/380168a0 8600393
81. Proinflammatory and vasoactive effects of Abeta in the cerebrovasculature. Townsend KP, Obregon D, Quadros A, Patel N, Volmar C, Paris D, Mullan M, Ann N Y Acad Sci 2002 977 65 76 10.1111/j.1749-6632.2002.tb04799.x 12480734
82. Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Kokjohn TA, van Vickle GD, Maarouf CL, Kalback WM, Hunter JM, Daugs ID, Luehrs DC, Lopez J, Brune D, Sue LI, Beach TG, Castano EM, Roher AE, Biochim Biophys Acta 1812 2011 1508 1514
83. Association of aortic atherosclerosis with cerebral beta-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Li L, Cao D, Garber DW, Kim H, Fukuchi K, Am J Pathol 2003 163 2155 2164 10.1016/S0002-9440(10) 63572-9 14633589
84. Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Tibolla G, Norata GD, Meda C, Arnaboldi L, Uboldi P, Piazza F, Ferrarese C, Corsini A, Maggi A, Vegeto E, Catapano AL, Atherosclerosis 2010 210 78 87 10.1016/j.atherosclerosis.2009.10.040 19945109
85. Attenuated atherogenesis in apolipoprotein E-deficient mice lacking amyloid precursor protein. van de Parre TJ, Guns PJ, Fransen P, Martinet W, Bult H, Herman AG, De Meyer GR, Atherosclerosis 2011 216 54 58 10.1016/j. atherosclerosis.2011.01.032 21316678
86. Apolipoprotein E is essential for amyloid deposition in the APP(V717F) transgenic mouse model of Alzheimer's disease. Bales KR, Verina T, Cummins DJ, Du Y, Dodel RC, Saura J, Fishman CE, DeLong CA, Piccardo P, Petegnief V, Ghetti B, Paul SM, Proc Natl Acad Sci U S A 1999 96 15233 15238 10.1073/pnas.96.26. 15233 10611368
87. Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in amyloid precursor protein transgenic mice. Fryer JD, Taylor JW, Demattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM, J Neurosci 2003 23 7889 7896 12944519
88. Cognitive impairment in PDAPP mice depends on ApoE and ACT-catalyzed amyloid formation. Nilsson LN, Arendash GW, Leighty RE, Costa DA, Low MA, Garcia MF, Cracciolo JR, Rojiani A, Wu X, Bales KR, Paul SM, Potter H, Neurobiol Aging 2004 25 1153 1167 10.1016/j.neurobiolaging.2003.12.011 15312961
89. Familial apolipoprotein E deficiency. Schaefer EJ, Gregg RE, Ghiselli G, Forte TM, Ordovas JM, Zech LA, Brewer HB Jr, J Clin Invest 1986 78 1206 1219 10.1172/JCI112704 3771793
90. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. van Eck M, Bos IS, Kaminski WE, Orso E, Rothe G, Twisk J, Bottcher A, Van Amersfoort ES, Christiansen-Weber TA, Fung-Leung WP, Van Berkel TJ, Schmitz G, Proc Natl Acad Sci U S A 2002 99 6298 6303 10.1073/pnas.092327399 11972062
91. Augmented atherogenesis in LDL receptor deficient mice lacking both macrophage ABCA1 and ApoE. Lammers B, Zhao Y, Hoekstra M, Hildebrand RB, Ye D, Meurs I, Van Berkel TJ, Van EM, PLoS One 2011 6 26095 10.1371/journal.pone. 0026095 22022523
92. Lack of ABCA1 considerably decreases brain ApoE level and increases amyloid deposition in APP23 mice. Koldamova R, Staufenbiel M, Lefterov I, J Biol Chem 2005 280 43224 43235 10.1074/jbc.M504513200 16207713
93. Absence of ACAT-1 attenuates atherosclerosis but causes dry eye and cutaneous xanthomatosis in mice with congenital hyperlipidemia. Yagyu H, Kitamine T, Osuga J, Tozawa R, Chen Z, Kaji Y, Oka T, Perrey S, Tamura Y, Ohashi K, Okazaki H, Yahagi N, Shionoiri F, Iizuka Y, Harada K, Shimano H, Yamashita H, Gotoda T, Yamada N, Ishibashi S, J Biol Chem 2000 275 21324 21330 10.1074/jbc.M002541200 10777503
94. Massive xanthomatosis and altered composition of atherosclerotic lesions in hyperlipidemic mice lacking acyl CoA:cholesterol acyltransferase 1. Accad M, Smith SJ, Newland DL, Sanan DA, King LE Jr, Linton MF, Fazio S, Farese RV Jr, J Clin Invest 2000 105 711 719 10.1172/JCI9021 10727439
95. Increased atherosclerosis in LDL receptor-null mice lacking ACAT1 in macrophages. Fazio S, Major AS, Swift LL, Gleaves LA, Accad M, Linton MF, Farese RV Jr, J Clin Invest 2001 107 163 171 10.1172/JCI10310 11160132
96. Reduced ABCA1-mediated cholesterol efflux and accelerated atherosclerosis in apolipoprotein E-deficient mice lacking macrophage-derived ACAT1. Su YR, Dove DE, Major AS, Hasty AH, Boone B, Linton MF, Fazio S, Circulation 2005 111 2373 2381 10.1161/01.CIR.0000164236.19860.13 15851589
97. ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Bryleva EY, Rogers MA, Chang CC, Buen F, Harris BT, Rousselet E, Seidah NG, Oddo S, LaFerla FM, Spencer TA, Hickey WF, Chang TY, Proc Natl Acad Sci U S A 2010 107 3081 3086 10.1073/pnas.0913828107 20133765
98. Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Willner EL, Tow B, Buhman KK, Wilson M, Sanan DA, Rudel LL, Farese RV Jr, Proc Natl Acad Sci U S A 2003 100 1262 1267 10.1073/pnas.0336398100 12538880
99. Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice. Bell TA III, Kelley K, Wilson MD, Sawyer JK, Rudel LL, Arterioscler Thromb Vasc Biol 2007 27 1396 1402 10.1161/ATVBAHA.107.142802 17431188
100. Loss of clusterin limits atherosclerosis in apolipoprotein E-deficient mice via reduced expression of Egr-1 and TNF-alpha. Hamada N, Miyata M, Eto H, Ikeda Y, Shirasawa T, Akasaki Y, Miyauchi T, Furusho Y, Nagaki A, Aronow BJ, Tei C, J Atheroscler Thromb 2011 18 209 216 10.5551/jat.5819 21099169
101. Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Demattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JA, Bales KR, Paul SM, Aronow BJ, Holtzman DM, Proc Natl Acad Sci U S A 2002 99 10843 10848 10.1073/pnas.162228299 12145324
102. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Demattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, Harmony JA, Aronow BJ, Bales KR, Paul SM, Holtzman DM, Neuron 2004 41 193 202 10.1016/S0896- 6273(03)00850-X 14741101
103. 27-Hydroxycholesterol, the first identified endogenous SERM, promotes atherogenesis in mice. Umetani M, Mangelsdorf DJ, Shaul PW, Circulation 2010 122 18427
104. Dehydroepiandrosterone 7-hydroxylase CYP7B: predominant expression in primate hippocampus and reduced expression in Alzheimer's disease. Yau JL, Rasmuson S, Andrew R, Graham M, Noble J, Olsson T, Fuchs E, Lathe R, Seckl JR, Neuroscience 2003 121 307 314 10.1016/S0306-4522(03)00438-X 14521990
105. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C, J Clin Invest 1997 99 2752 2761 10.1172/JCI119465 9169506
106. Interferon-gamma and tumor necrosis factor-alpha regulate amyloid-beta plaque deposition and beta-secretase expression in Swedish mutant APP transgenic mice. Yamamoto M, Kiyota T, Horiba M, Buescher JL, Walsh SM, Gendelman HE, Ikezu T, Am J Pathol 2007 170 680 692 10.2353/ajpath.2007.060378 17255335
107. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. Fryer JD, Demattos RB, McCormick LM, O'Dell MA, Spinner ML, Bales KR, Paul SM, Sullivan PM, Parsadanian M, Bu G, Holtzman DM, J Biol Chem 2005 280 25754 25759 10.1074/jbc.M502143200 15888448
108. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Cao D, Fukuchi K, Wan H, Kim H, Li L, Neurobiol Aging 2006 27 1632 1643 10.1016/j.neurobiolaging.2005.09.011 16236385
109. Lack of LDL receptor enhances amyloid deposition and decreases glial response in an Alzheimer's disease mouse model. Katsouri L, Georgopoulos S, PLoS One 2011 6 21880 10.1371/journal.pone.0021880 21755005
110. Disruption of the acyl-CoA:cholesterol acyltransferase gene in mice: evidence suggesting multiple cholesterol esterification enzymes in mammals. Meiner VL, Cases S, Myers HM, Sande ER, Bellosta S, Schambelan M, Pitas RE, McGuire J, Herz J, Farese RV Jr, Proc Natl Acad Sci U S A 1996 93 14041 14046 10.1073/pnas.93.24.14041 8943057
111. Acyl-coenzyme A: cholesterol acyltransferases. Chang TY, Li BL, Chang CC, Urano Y, Am J Physiol Endocrinol Metab 2009 297 1 E9 10.1152/ajpendo.90926.2008 19141679
112. C-reactive Protein. Black S, Kushner I, Samols D, J Biol Chem 2004 279 48487 48490 10.1074/jbc.R400025200 15337754
113. C-reactive protein in atherosclerosis: A causal factor? Paffen E, DeMaat MP, Cardiovasc Res 2006 71 30 39 10.1016/j.cardiores.2006.03.004 16624260
114. C-reactive protein immunohistochemical localization in normal and atherosclerotic human aortas. Reynolds GD, Vance RP, Arch Pathol Lab Med 1987 111 265 269 2435257
115. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Yasojima K, Schwab C, McGeer EG, McGeer PL, Brain Res 2000 887 80 89 10.1016/S0006-8993(00)02970-X 11134592
116. Inflammation of the brain in Alzheimer's disease: implications for therapy. McGeer PL, McGeer EG, J Leukoc Biol 1999 65 409 415 10204568
117. Inflammation and Alzheimer's disease. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, et al. Neurobiol Aging 2000 21 383 421 10.1016/S0197-4580(00)00124-X 10858586
118. Inflammation and atherosclerosis. Hansson GK, Robertson AK, Soderberg-Naucler C, Annu Rev Pathol 2006 1 297 329 10.1146/annurev.pathol.1. 110304.100100 18039117
119. Inflammation in atherosclerosis. Libby P, Arterioscler Thromb Vasc Biol 2012 32 2045 2051 10.1161/ATVBAHA.108.179705 22895665
120. Role of macrophage colony-stimulating factor in atherosclerosis: studies of osteopetrotic mice. Qiao JH, Tripathi J, Mishra NK, Cai Y, Tripathi S, Wang XP, Imes S, Fishbein MC, Clinton SK, Libby P, Lusis AJ, Rajavashisth TB, Am J Pathol 1997 150 1687 1699 9137093
121. Lymphocytes are important in early atherosclerosis. Song L, Leung C, Schindler C, J Clin Invest 2001 108 251 259 10.1172/JCI200111380 11457878
122. Total lymphocyte deficiency attenuates AngII-induced atherosclerosis in males but not abdominal aortic aneurysms in apoE deficient mice. Uchida HA, Kristo F, Rateri DL, Lu H, Charnigo R, Cassis LA, Daugherty A, Atherosclerosis 2010 211 399 403 10.1016/j.atherosclerosis.2010.02.034 20362292
123. B cell depletion reduces the development of atherosclerosis in mice. Ait-Oufella H, Herbin O, Bouaziz JD, Binder CJ, Uyttenhove C, Laurans L, Taleb S, Van VE, Esposito B, Vilar J, Sirvent J, Van SJ, Tedgui A, Tedder TF, Mallat Z, J Exp Med 2010 207 1579 1587 10.1084/jem.20100155 20603314
124. Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. el Khoury J, Toft M, Hickman SE, Means TK, Terada K, Geula C, Luster AD, Nat Med 2007 13 432 438 10.1038/nm1555 17351623
125. Connecting TNF-alpha signaling pathways to iNOS expression in a mouse model of Alzheimer's disease: relevance for the behavioral and synaptic deficits induced by amyloid beta protein. Medeiros R, Prediger RD, Passos GF, Pandolfo P, Duarte FS, Franco JL, Dafre AL, Di GG, Figueiredo CP, Takahashi RN, Campos MM, Calixto JB, J Neurosci 2007 27 5394 5404 10.1523/JNEUROSCI.5047-06.2007 17507561
126. Deletion of CD14 attenuates Alzheimer's disease pathology by influencing the brain's inflammatory milieu. Reed-Geaghan EG, Reed QW, Cramer PE, Landreth GE, J Neurosci 2010 30 15369 15373 10.1523/JNEUROSCI.2637-10.2010 21084593
127. Ablation of the microglial protein DOCK2 reduces amyloid burden in a mouse model of Alzheimer's disease. Cimino PJ, Yang Y, Li X, Hemingway JF, Cherne MK, Khademi SB, Fukui Y, Montine KS, Montine TJ, Keene CD, Exp Mol Pathol 2013 94 366 371 10.1016/j.yexmp.2013.01.002 23318649
128. Bone marrow transplantation in apolipoprotein E-deficient mice. Effect of ApoE gene dosage on serum lipid concentrations, (beta)VLDL catabolism, and atherosclerosis. van Eck M, Herijgers N, Yates J, Pearce NJ, Hoogerbrugge PM, Groot PH, Van Berkel TJ, Arterioscler Thromb Vasc Biol 1997 17 3117 3126 10.1161/01.ATV.17.11.3117 9409301
129. Low density lipoprotein receptor of macrophages facilitates atherosclerotic lesion formation in C57Bl/6 mice. Herijgers N, Van EM, Groot PH, Hoogerbrugge PM, van Berkel TJ, Arterioscler Thromb Vasc Biol 2000 20 1961 1967 10.1161/01.ATV.20.8.1961 10938018
130. Physiological expression of macrophage apoE in the artery wall reduces atherosclerosis in severely hyperlipidemic mice. Fazio S, Babaev VR, Burleigh ME, Major AS, Hasty AH, Linton MF, J Lipid Res 2002 43 1602 1609 10.1194/jlr.M200108-JLR200 12364544
131. Enhanced foam cell formation, atherosclerotic lesion development, and inflammation by combined deletion of ABCA1 and SR-BI in Bone marrow-derived cells in LDL receptor knockout mice on western-type diet. Zhao Y, Pennings M, Hildebrand RB, Ye D, Calpe-Berdiel L, Out R, Kjerrulf M, Hurt-Camejo E, Groen AK, Hoekstra M, Jessup W, Chimini G, Van Berkel TJ, Van EM, Circ Res 2010 107 20 e31 10.1161/CIRCRESAHA.110.226282 21071707
132. Suppressed accumulation of cerebral amyloid beta peptides in aged transgenic Alzheimer's disease mice by transplantation with wild-type or prostaglandin E2 receptor subtype 2-null bone marrow. Keene CD, Chang RC, Lopez-Yglesias AH, Shalloway BR, Sokal I, Li X, Reed PJ, Keene LM, Montine KS, Breyer RM, Rockhill JK, Montine TJ, Am J Pathol 2010 177 346 354 10.2353/ajpath.2010.090840 20522650
133. Myeloid differentiation factor 88-deficient bone marrow cells improve Alzheimer's disease-related symptoms and pathology. Hao W, Liu Y, Liu S, Walter S, Grimm MO, Kiliaan AJ, Penke B, Hartmann T, Rube CE, Menger MD, Fassbender K, Brain 2011 134 278 292 10.1093/brain/awq325 21115468
134. Mutant presenilin-1 deregulated peripheral immunity exacerbates Alzheimer-like pathology. Zhu Y, Obregon D, Hou H, Giunta B, Ehrhart J, Fernandez F, Mori T, Nikolic W, Zhao Y, Morgan D, Town T, Tan J, J Cell Mol Med 2011 15 327 338 10.1111/j.1582-4934.2009.00962.x 19900216
135. APOE3, but not APOE4, bone marrow transplantation mitigates behavioral and pathological changes in a mouse model of Alzheimer disease. Yang Y, Cudaback E, Jorstad NL, Hemingway JF, Hagan CE, Melief EJ, Li X, Yoo T, Khademi SB, Montine KS, Montine TJ, Keene CD, Am J Pathol 2013 183 905 917 10.1016/j.ajpath.2013.05.009 23831297
136. Macrophages in the pathogenesis of atherosclerosis. Moore KJ, Tabas I, Cell 2011 145 341 355 10.1016/j.cell.2011.04.005 21529710
137. Cyclooxygenase-2-positive macrophages infiltrate the Alzheimer's disease brain and damage the blood-brain barrier. Fiala M, Liu QN, Sayre J, Pop V, Brahmandam V, Graves MC, Vinters HV, Eur J Clin Invest 2002 32 360 371 10.1046/j.1365-2362.2002.00994.x 12027877
138. Effect of macrophage ApoE on atherosclerosis in LDL-receptor deficient mice. Tennert C, Teupser D, Mueller MA, Wilfert W, Renner-Muller I, Stein O, Stein Y, Sippel AE, Wolf E, Thiery J, Biochem Biophys Res Commun 2007 361 574 579 10.1016/j.bbrc.2007.07.067 17669363
139. Macrophage-specific apoE gene repair reduces diet-induced hyperlipidemia and atherosclerosis in hypomorphic Apoe mice. Gaudreault N, Kumar N, Olivas VR, Eberle D, Rapp JH, Raffai RL, PLoS One 2012 7 35816 10.1371/journal.pone.0035816 22606237
140. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF, Arterioscler Thromb Vasc Biol 2005 25 1647 1653 10.1161/01.ATV.0000173413.31789.1a 15947238
141. Deletion of macrophage LDL receptor-related protein increases atherogenesis in the mouse. Overton CD, Yancey PG, Major AS, Linton MF, Fazio S, Circ Res 2007 100 670 677 10.1161/01.RES.0000260204.40510.aa 17303763
142. The role of microglial cells and astrocytes in fibrillar plaque evolution in transgenic APP(SW) mice. Wegiel J, Wang KC, Imaki H, Rubenstein R, Wronska A, Osuchowski M, Lipinski WJ, Walker LC, LeVine H, Neurobiol Aging 2001 22 49 61 10.1016/S0197-4580(00)00181-0 11164276
143. Cells of monocyte/microglial lineage are involved in both microvessel amyloidosis and fibrillar plaque formation in APPsw tg mice. Wegiel J, Imaki H, Wang KC, Wegiel J, Rubenstein R, Brain Res 2004 1022 19 29 10.1016/j.brainres. 2004.06.058 15353209
144. Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S, Neuron 2006 49 489 502 10.1016/j.neuron.2006.01.022 16476660
145. Formation and maintenance of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Grathwohl SA, Kalin RE, Bolmont T, Prokop S, Winkelmann G, Kaeser SA, Odenthal J, Radde R, Eldh T, Gandy S, Aguzzi A, Staufenbiel M, Mathews PM, Wolburg H, Heppner FL, Jucker M, Nat Neurosci 2009 12 1361 1363 10.1038/nn.2432 19838177
146. Selective targeting of perivascular macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Hawkes CA, McLaurin J, Proc Natl Acad Sci U S A 2009 106 1261 1266 10.1073/pnas.0805453106 19164591
147. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA, Nat Med 2008 14 681 687 18516051
148. Macrophages in Alzheimer's disease: the blood-borne identity. Gate D, Rezai-Zadeh K, Jodry D, Rentsendorj A, Town T, J Neural Transm 2010 117 961 970 10.1007/s00702-010-0422-7 20517700
149. How to get from here to there: macrophage recruitment in Alzheimer's disease. Rezai-Zadeh K, Gate D, Gowing G, Town T, Curr Alzheimer Res 2011 8 156 163 10.2174/156720511795256017 21345166
150. One hundred years of discovery and rediscovery of Helicobacter pylori and its association with peptic ulcer disease. Marshall BJ, Helicobacter pylori: Physiology and Genetics Washington DC: ADM Press, Mobley HLT, Mendz GL, Hazell SL, 2001 Chapter 3
151. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Marshall BJ, Warren JR, Lancet 1984 1 1311 1315 6145023
152. Trans-synaptic spread of tau pathology in vivo. Liu L, Drouet V, Wu JW, Witter MP, Small SA, Clelland C, Duff K, PLoS One 2012 7 31302 10.1371/journal.pone.0031302 22312444
153. Propagation of tau pathology in a model of early Alzheimer's disease. de Calignon A, Polydoro M, Suarez-Calvet M, William C, Adamowicz DH, Kopeikina KJ, Pitstick R, Sahara N, Ashe KH, Carlson GA, Spires-Jones TL, Hyman BT, Neuron 2012 73 685 697 10.1016/j.neuron.2011.11.033 22365544
154. Induction of beta (A4)-amyloid in primates by injection of Alzheimer's disease brain homogenate. Comparison with transmission of spongiform encephalopathy. Baker HF, Ridley RM, Duchen LW, Crow TJ, Bruton CJ, Mol Neurobiol 1994 8 25 39 10.1007/BF02778005 8086126
155. Very long term studies of the seeding of beta-amyloidosis in primates. Ridley RM, Baker HF, Windle CP, Cummings RM, J Neural Transm 2006 113 1243 1251 10.1007/s00702-005-0385-2 16362635
156. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Jucker M, Walker LC, Ann Neurol 2011 70 532 540 10.1002/ana.22615 22028219
157. Evidence for seeding of beta -amyloid by intracerebral infusion of Alzheimer brain extracts in beta -amyloid precursor protein-transgenic mice. Kane MD, Lipinski WJ, Callahan MJ, Bian F, Durham RA, Schwarz RD, Roher AE, Walker LC, J Neurosci 2000 20 3606 3611 10804202
158. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM, Ghiso J, Staufenbiel M, Walker LC, Jucker M, Science 2006 313 1781 1784 10.1126/science.1131864 16990547
159. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M, Proc Natl Acad Sci U S A 2009 106 12926 12931 10.1073/pnas.0903200106 19622727
160. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M, Science 2010 330 980 982 10.1126/science.1194516 20966215
161. Soluble Abeta seeds are potent inducers of cerebral beta-amyloid deposition. Langer F, Eisele YS, Fritschi SK, Staufenbiel M, Walker LC, Jucker M, J Neurosci 2011 31 14488 14495 10.1523/JNEUROSCI.3088-11.2011 21994365
162. De novo induction of amyloid-beta deposition in vivo. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C, Mol Psychiatry 2012 17 1347 1353 10.1038/mp.2011.120 21968933
163. Exogenous seeding of cerebral beta-amyloid deposition in betaAPP-transgenic rats. Rosen RF, Fritz JJ, Dooyema J, Cintron AF, Hamaguchi T, Lah JJ, LeVine H III, Jucker M, Walker LC, J Neurochem 2012 120 660 666 10.1111/j.1471-4159.2011.07551.x 22017494
164. Induction of tau pathology by intracerebral infusion of amyloid-beta -containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M, Am J Pathol 2007 171 2012 2020 10.2353/ajpath.2007.070403 18055549
165. Inducible proteopathies. Walker LC, LeVine H III, Mattson MP, Jucker M, Trends Neurosci 2006 29 438 443 10.1016/j.tins.2006.06.010 16806508
166. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Hardy J, Selkoe DJ, Science 2002 297 353 356 10.1126/science.1072994 12130773
167. Miliare Nekrosen mit drusigen Wucherungen der Neurofibrillen, eine regelmässige Veränderung der Hirnrinde bei seniler Demenz. Fischer O, Monatschr f Psychiat Neurol 1907 22 372
168. Emerging roles of pathogens in Alzheimer disease. Miklossy J, Expert Rev Mol Med 2011 13 30 21933454
169. Chlamydia pneumoniae infection and Alzheimer's disease: a connection to remember? Shima K, Kuhlenbaumer G, Rupp J, Med Microbiol Immunol 2010 199 283 289 10.1007/s00430-010-0162-1 20445987
170. Infectious agents and neurodegeneration. De CG, Marcocci ME, Sgarbanti R, Civitelli L, Ripoli C, Piacentini R, Garaci E, Grassi C, Palamara AT, Mol Neurobiol 2012 46 614 638 10.1007/s12035-012-8320-7 22899188
171. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Honjo K, van RR, Verhoeff NP, Alzheimers Dement 2009 5 348 360 10.1016/j.jalz.2008.12.001 19560105
172. Viruses, Parkinsonism and Alzheimer's Disease. Mann DMA, Tates PP, Davides JS, Hawkes J, J Neurol Neurosurg Psychiat 1981 44 651 10.1136/jnnp.44.7.651 6270283
173. Viruses and Alzheimer's disease. Esiri MM, J Neurol Neurosurg Psychiatry 1982 45 759 760 6752349
174. Reactivation of HSV-1 in the brain of patients with familial Alzheimer's disease. Mori I, Kimura Y, Naiki H, Matsubara R, Takeuchi T, Yokochi T, Nishiyama Y, J Med Virol 2004 73 605 611 10.1002/jmv.20133 15221907
175. In situ hybridization analysis for herpes simplex virus nucleic acids in Alzheimer disease. Walker DG, O'Kusky JR, McGeer PL, Alzheimer Dis Assoc Disord 1989 3 123 131 10.1097/00002093-198903030-00001 2551348
176. Seropositivity to herpes simplex virus antibodies and risk of Alzheimer's disease: a population-based cohort study. Letenneur L, Peres K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF, PLoS One 2008 3 3637 10.1371/journal.pone.0003637 18982063
177. Identification and localization of Chlamydia pneumoniae in the Alzheimer's brain. Balin BJ, Gerard HC, Arking EJ, Appelt DM, Branigan PJ, Abrams JT, Whittum-Hudson JA, Hudson AP, Med Microbiol Immunol 1998 187 23 42 10.1007/s004300050071 9749980
178. Chlamydophila (Chlamydia) pneumoniae in the Alzheimer's brain. Gerard HC, Dreses-Werringloer U, Wildt KS, Deka S, Oszust C, Balin BJ, Frey WH, Bordayo EZ, Whittum-Hudson JA, Hudson AP, FEMS Immunol Med Microbiol 2006 48 355 366 10.1111/j.1574-695X.2006.00154.x 17052268
179. Immunohistological detection of Chlamydia pneumoniae in the Alzheimer's disease brain. Hammond CJ, Hallock LR, Howanski RJ, Appelt DM, Little CS, Balin BJ, BMC Neurosci 2010 11 121 10.1186/1471-2202-11-121 20863379
180. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease. Riviere GR, Riviere KH, Smith KS, Oral Microbiol Immunol 2002 17 113 118 10.1046/j.0902-0055.2001.00100.x 11929559
181. Alzheimer's disease-a spirochetosis? Miklossy J, Neuroreport 1993 4 841 848 10.1097/00001756-199307000-00002 8369471
182. Relationship between Helicobacter pylori infection and Alzheimer disease. Kountouras J, Tsolaki M, Gavalas E, Boziki M, Zavos C, Karatzoglou P, Chatzopoulos D, Venizelos I, Neurology 2006 66 938 940 10.1212/01.wnl. 0000203644.68059.5f 16567719
183. Impact of chronic Helicobacter pylori infection on Alzheimer's disease: preliminary results. Roubaud-Baudron C, Krolak-Salmon P, Quadrio I, Megraud F, Salles N, Neurobiol Aging 2012 33 1009
184. Does Helicobacter pylori infection increase incidence of dementia? The Personnes Agées QUID Study. Roubaud-Baudron C, Letenneur L, Langlais A, Buissonniere A, Megraud F, Dartigues JF, Salles N, J Am Geriatr Soc 2013 61 74 78 10.1111/jgs.12065 23252507
185. The relationship between Helicobacter pylori infection and Alzheimer's disease in Japan. Shiota S, Murakami K, Yoshiiwa A, Yamamoto K, Ohno S, Kuroda A, Mizukami K, Hanada K, Okimoto T, Kodama M, Abe K, Yamaoka Y, Fujioka T, J Neurol 2011 258 1460 1463 10.1007/s00415-011-5957-5 21336779
186. Five-year survival after Helicobacter pylori eradication in Alzheimer disease patients. Kountouras J, Boziki M, Gavalas E, Zavos C, Deretzi G, Chatzigeorgiou S, Katsinelos P, Grigoriadis N, Giartza-Taxidou E, Venizelos I, Cogn Behav Neurol 2010 23 199 204 20829670
187. Viruses in the etiology of atherosclerosis. Benditt EP, Barrett T, McDougall JK, Proc Natl Acad Sci U S A 1983 80 6386 6389 10.1073/pnas.80.20.6386 6312457
188. The presence of cytomegalovirus nucleic acids in arterial walls of atherosclerotic and nonatherosclerotic patients. Hendrix MG, Dormans PH, Kitslaar P, Bosman F, Bruggeman CA, Am J Pathol 1989 134 1151 1157 2541613
189. Cytomegalovirus antigen within human arterial smooth muscle cells. Melnick JL, Petrie BL, Dreesman GR, Burek J, McCollum CH, DeBakey ME, Lancet 1983 2 644 647 6136795
190. Nucleic acid sequences of cytomegalovirus in cells cultured from human arterial tissue. Petrie BL, Melnick JL, Adam E, Burek J, McCollum CH, DeBakey ME, J Infect Dis 1987 155 158 159 10.1093/infdis/155.1.158 3025305
191. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE, Science 1994 265 391 394 10.1126/science.8023160 8023160
192. Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE, N Engl J Med 1996 335 624 630 10.1056/ NEJM199608293350903 8687516
193. Human cytomegalovirus seropositivity is associated with impaired vascular function. Grahame-Clarke C, Chan NN, Andrew D, Ridgway GL, Betteridge DJ, Emery V, Colhoun HM, Vallance P, Circulation 2003 108 678 683 10.1161/01.CIR. 0000084505.54603.C7 12900349
194. Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M, Circulation 1996 94 922 927 10.1161/01.CIR.94.5.922 8790026
195. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. Shor A, Kuo CC, Patton DL, S Afr Med J 1992 82 158 161 1519134
196. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Kuo CC, Gown AM, Benditt EP, Grayston JT, Arterioscler Thromb 1993 13 1501 1504 10.1161/01.ATV.13.10.1501 7691166
197. Chlamydia pneumoniae and vascular disease. Gibbs RG, Carey N, Davies AH, Br J Surg 1998 85 1191 1197 10.1046/j.1365-2168.1998.00861.x 9752857
198. Detection of Chlamydia pneumoniae and Helicobacter pylori in atherosclerotic plaques of carotid artery by polymerase chain reaction. Kaplan M, Yavuz SS, Cinar B, Koksal V, Kut MS, Yapici F, Gercekoglu H, Demirtas MM, Int J Infect Dis 2006 10 116 123 10.1016/j.ijid.2004.10.008 16183317
199. Chlamydophila pneumoniae infection leads to smooth muscle cell proliferation and thickening in the coronary artery without contributions from a host immune response. Deniset JF, Cheung PK, Dibrov E, Lee K, Steigerwald S, Pierce GN, Am J Pathol 2010 176 1028 1037 10.2353/ajpath.2010.090645 20019196
200. Chlamydia pneumoniae as an emerging risk factor in cardiovascular disease. Kalayoglu MV, Libby P, Byrne GI, JAMA 2002 288 2724 2731 10.1001/jama.288.21.2724 12460096
201. Role of Chlamydia pneumoniae in atherosclerosis. Watson C, Alp NJ, Clin Sci (Lond) 2008 114 509 531 10.1042/CS20070298 18336368
202. Detection of Helicobacter pylori in human carotid atherosclerotic plaques. Ameriso SF, Fridman EA, Leiguarda RC, Sevlever GE, Stroke 2001 32 385 391 10.1161/01.STR.32.2.385 11157171
203. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms. Blasi F, Denti F, Erba M, Cosentini R, Raccanelli R, Rinaldi A, Fagetti L, Esposito G, Ruberti U, Allegra L, J Clin Microbiol 1996 34 2766 2769 8897180
204. Detection of Treponema denticola in atherosclerotic lesions. Okuda K, Ishihara K, Nakagawa T, Hirayama A, Inayama Y, Okuda K, J Clin Microbiol 2001 39 1114 1117 10.1128/JCM.39.3.1114-1117.2001 11230436
205. Commonality in chronic inflammatory diseases: periodontitis, diabetes, and coronary artery disease. Southerland JH, Taylor GW, Moss K, Beck JD, Offenbacher S, Periodontol 2000 2006 40 130 143 10.1111/j.1600-0757.2005.00138.x 16398690
206. Association between dental health and acute myocardial infarction. Mattila KJ, Nieminen MS, Valtonen VV, Rasi VP, Kesaniemi YA, Syrjala SL, Jungell PS, Isoluoma M, Hietaniemi K, Jokinen MJ, BMJ 1989 298 779 781 10.1136/bmj.298.6676.779 2496855
207. The relationship between dental disease and cerebral vascular accident in elderly United States veterans. Loesche WJ, Schork A, Terpenning MS, Chen YM, Kerr C, Dominguez BL, Ann Periodontol 1998 3 161 174 10.1902/annals.1998.3.1.161 9722700
208. Detection and localization of periodontopathic bacteria in abdominal aortic aneurysms. Kurihara N, Inoue Y, Iwai T, Umeda M, Huang Y, Ishikawa I, Eur J Vasc Endovasc Surg 2004 28 553 558 10.1016/j.ejvs.2004.08.010 15465379
209. Evaluation of the incidence of periodontitis-associated bacteria in the atherosclerotic plaque of coronary blood vessels. Zaremba M, Gorska R, Suwalski P, Kowalski J, J Periodontol 2007 78 322 327 10.1902/jop.2006.060081 17274722
210. Roles of oral bacteria in cardiovascular diseases-from molecular mechanisms to clinical cases: Involvement of Porphyromonas gingivalis in the development of human aortic aneurysm. Wada K, Kamisaki Y, J Pharmacol Sci 2010 113 115 119 10.1254/jphs.09R22FM 20501967
211. Atherosclerosis and infection: is the jury still not in? Chatzidimitriou D, Kirmizis D, Gavriilaki E, Chatzidimitriou M, Malisiovas N, Future Microbiol 2012 7 1217 1230 10.2217/fmb.12.87 23030426
212. Periodontal bacteria and hypertension: the oral infections and vascular disease epidemiology study (INVEST). Desvarieux M, Demmer RT, Jacobs DR Jr, Rundek T, Boden-Albala B, Sacco RL, Papapanou PN, J Hypertens 2010 28 1413 1421 10.1097/HJH.0b013e328338cd36 20453665
213. Is atherosclerosis an infectious disease? Mawhorter SD, Lauer MA, Cleve Clin J Med 2001 68 449 458 10.3949/ccjm.68.5.449 11352325
214. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: a meta-analysis of randomized controlled trials. Andraws R, Berger JS, Brown DL, JAMA 2005 293 2641 2647 10.1001/jama.293.21.2641 15928286
215. Atheroarteriosclerosis induced by infection with a herpesvirus. Minick CR, Fabricant CG, Fabricant J, Litrenta MM, Am J Pathol 1979 96 673 706 382868
216. Warner-Lambert/Parke-Davis Award Lecture. Viral pathogenesis of atherosclerosis. Impact of molecular mimicry and viral genes. Hajjar DP, Am J Pathol 1991 139 1195 1211 1661071
217. Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Little CS, Hammond CJ, MacIntyre A, Balin BJ, Appelt DM, Neurobiol Aging 2004 25 419 429 10.1016/S0197-4580(03)00127-1 15013562
218. Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Wozniak MA, Itzhaki RF, Shipley SJ, Dobson CB, Neurosci Lett 2007 429 95 100 10.1016/j.neulet.2007.09.077 17980964
219. Inflammation induced by infection potentiates tau pathological features in transgenic mice. Sy M, Kitazawa M, Medeiros R, Whitman L, Cheng D, Lane TE, LaFerla FM, Am J Pathol 2011 178 2811 2822 10.1016/j.ajpath.2011.02.012 21531375
220. Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. Green DA, Masliah E, Vinters HV, Beizai P, Moore DJ, Achim CL, AIDS 2005 19 407 411 10.1097/01.aids.0000161770.06158.5c 15750394
221. Toxoplasma gondii infection in the brain inhibits neuronal degeneration and learning and memory impairments in a murine model of Alzheimer's disease. Jung BK, Pyo KH, Shin KY, Hwang YS, Lim H, Lee SJ, Moon JH, Lee SH, Suh YH, Chai JY, Shin EH, PLoS One 2012 7 33312 10.1371/journal.pone.0033312 22470449
222. Murine models of Chlamydia pneumoniae infection and atherosclerosis. Moazed TC, Kuo C, Grayston JT, Campbell LA, J Infect Dis 1997 175 883 890 10.1086/513986 9086145
223. Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months. Liu L, Hu H, Ji H, Murdin AD, Pierce GN, Zhong G, Mol Cell Biochem 2000 215 123 128 10.1023/A:1026531506202 11204447
224. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr-/- mice. Hauer AD, de VP, Peterse N, ten CH, van Berkel TJ, Stassen FR, Kuiper J, Cardiovasc Res 2006 69 280 288 10.1016/j.cardiores. 2005.07.011 16112098
225. Chlamydia pneumoniae does not increase atherosclerosis in the aortic root of apolipoprotein E-deficient mice. Aalto-Setala K, Laitinen K, Erkkila L, Leinonen M, Jauhiainen M, Ehnholm C, Tamminen M, Puolakkainen M, Penttila I, Saikku P, Arterioscler Thromb Vasc Biol 2001 21 578 584 10.1161/01.ATV.21.4.578 11304476
226. Chlamydia pneumoniae infection does not induce or modify atherosclerosis in mice. Caligiuri G, Rottenberg M, Nicoletti A, Wigzell H, Hansson GK, Circulation 2001 103 2834 2838 10.1161/01.CIR.103.23.2834 11401941
227. Chlamydia pneumoniae-induced macrophage foam cell formation is mediated by Toll-like receptor 2. Cao F, Castrillo A, Tontonoz P, Re F, Byrne GI, Infect Immun 2007 75 753 759 10.1128/IAI.01386-06 17145941
228. Chlamydia pneumoniae infection of human endothelial cells induces proliferation of smooth muscle cells via an endothelial cell-derived soluble factor(s). Coombes BK, Mahony JB, Infect Immun 1999 67 2909 2915 10338498
229. Pathogen-accelerated atherosclerosis occurs early after exposure and can be prevented via immunization. Miyamoto T, Yumoto H, Takahashi Y, Davey M, Gibson FC III, Genco CA, Infect Immun 2006 74 1376 1380 10.1128/IAI.74.2.1376- 1380.2006 16428788
230. Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. Hayashi C, Papadopoulos G, Gudino CV, Weinberg EO, Barth KR, Madrigal AG, Chen Y, Ning H, LaValley M, Gibson FC III, Hamilton JA, Genco CA, J Immunol 2012 189 3681 3688 10.4049/jimmunol.1201541 22956579
231. Regulation of cellular immunity prevents Helicobacter pylori-induced atherosclerosis. Ayada K, Yokota K, Hirai K, Fujimoto K, Kobayashi K, Ogawa H, Hatanaka K, Hirohata S, Yoshino T, Shoenfeld Y, Matsuura E, Oguma K, Lupus 2009 18 1154 1168 10.1177/0961203309106600 19880562
232. Increased atherogenesis during Streptococcus mutans infection in ApoE-null mice. Kesavalu L, Lucas AR, Verma RK, Liu L, Dai E, Sampson E, Progulske-Fox A, J Dent Res 2012 91 255 260 10.1177/0022034511435101 22262633
233. Herpesvirus infection accelerates atherosclerosis in the apolipoprotein E-deficient mouse. Alber DG, Powell KL, Vallance P, Goodwin DA, Grahame-Clarke C, Circulation 2000 102 779 785 10.1161/01.CIR.102.7.779 10942747
234. Influenza infection exerts prominent inflammatory and thrombotic effects on the atherosclerotic plaques of apolipoprotein E-deficient mice. Naghavi M, Wyde P, Litovsky S, Madjid M, Akhtar A, Naguib S, Siadaty MS, Sanati S, Casscells W, Circulation 2003 107 762 768 10.1161/01.CIR.0000048190.68071.2B 12578882
235. Cytomegalovirus infection increases development of atherosclerosis in Apolipoprotein-E knockout mice. Hsich E, Zhou YF, Paigen B, Johnson TM, Burnett MS, Epstein SE, Atherosclerosis 2001 156 23 28 10.1016/S0021-9150(00)00608-0 11368993
236. Cytomegalovirus infection aggravates atherogenesis in apoE knockout mice by both local and systemic immune activation. Vliegen I, Duijvestijn A, Grauls G, Herngreen S, Bruggeman C, Stassen F, Microbes Infect 2004 6 17 24 10.1016/j.micinf.2003.09.024 14738889
237. An anti-atherogenic effect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol. Doenhoff MJ, Stanley RG, Griffiths K, Jackson CL, Parasitology 2002 125 415 421 12458825
238. Infectious agents are not necessary for murine atherogenesis. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, Patel S, Card DJ, Hermanowski-Vosatka A, Bergstrom JD, Sparrow CP, Detmers PA, Chao YS, J Exp Med 2000 191 1437 1442 10.1084/jem.191.8.1437 10770809
239. Implication of natural killer T cells in atherosclerosis development during a LPS-induced chronic inflammation. Ostos MA, Recalde D, Zakin MM, Scott-Algara D, FEBS Lett 2002 519 23 29 10.1016/S0014-5793(02)02692-3 12023012
240. Mouse cytomegalovirus antigenic immune stimulation is sufficient to aggravate atherosclerosis in hypercholesterolemic mice. Vliegen I, Herngreen SB, Grauls GE, Bruggeman CA, Stassen FR, Atherosclerosis 2005 181 39 44 10.1016/j.atherosclerosis.2004.12.035 15939052
241. Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice. Krstic D, Madhusudan A, Doehner J, Vogel P, Notter T, Imhof C, Manalastas A, Hilfiker M, Pfister S, Schwerdel C, Riether C, Meyer U, Knuesel I, J Neuroinflammation 2012 9 151 10.1186/1742-2094-9-151 22747753
242. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT, J Neuroinflammation 2008 5 37 10.1186/1742-2094-5-37 18759972
243. Insights into the role of infection in atherogenesis and in plaque rupture. Epstein SE, Zhu J, Najafi AH, Burnett MS, Circulation 2009 119 3133 3141 10.1161/CIRCULATIONAHA.109.849455 19546396
244. Can statins prevent or help treat Alzheimer's disease? McGuinness B, Passmore P, J Alzheimers Dis 2010 20 925 933 20182019
245. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Ballantyne CM, Raichlen JS, Nicholls SJ, Erbel R, Tardif JC, Brener SJ, Cain VA, Nissen SE, Circulation 2008 117 2458 2466 10.1161/CIRCULATIONAHA.108.773747 18378607
246. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM, JAMA 2006 295 1556 1565 10.1001/jama.295.13.jpc60002 16533939
247. Coronary atherosclerosis can regress with very intensive statin therapy. Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE, Cleve Clin J Med 2006 73 937 944 10.3949/ccjm.73.10.937 17044319
248. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. Lim GP, Chu T, Yang F, Beech W, Frautschy SA, Cole GM, J Neurosci 2001 21 8370 8377 11606625
249. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, Chen PP, Kayed R, Glabe CG, Frautschy SA, Cole GM, J Biol Chem 2005 280 5892 5901 15590663
250. Curcumin labels amyloid pathology in vivo, disrupts existing plaques, and partially restores distorted neurites in an Alzheimer mouse model. Garcia-Alloza M, Borrelli LA, Rozkalne A, Hyman BT, Bacskai BJ, J Neurochem 2007 102 1095 1104 10.1111/j.1471-4159.2007.04613.x 17472706
251. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. Begum AN, Jones MR, Lim GP, Morihara T, Kim P, Heath DD, Rock CL, Pruitt MA, Yang F, Hudspeth B, Hu S, Faull KF, Teter B, Cole GM, Frautschy SA, J Pharmacol Exp Ther 2008 326 196 208 10.1124/jpet.108.137455 18417733
252. Curcuminoids rescue long-term potentiation impaired by amyloid peptide in rat hippocampal slices. Ahmed T, Gilani AH, Hosseinmardi N, Semnanian S, Enam SA, Fathollahi Y, Synapse 2011 65 572 582 10.1002/syn.20876 20963814
253. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. Baum L, Lam CW, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Goggins WB, Zee BC, Cheng KF, Fong CY, Wong A, Mok H, Chow MS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CY, Chan MH, Szeto S, Chan IH, Mok V, J Clin Psychopharmacol 2008 28 110 113 10.1097/jcp.0b013e318160862c 18204357
254. Effect of curcumin on atherosclerosis in apoE/LDLR-double knockout mice. Olszanecki R, Jawien J, Gajda M, Mateuszuk L, Gebska A, Korabiowska M, Chlopicki S, Korbut R, J Physiol Pharmacol 2005 56 627 635 16391419
255. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Shin SK, Ha TY, McGregor RA, Choi MS, Mol Nutr Food Res 2011 55 1829 1840 10.1002/mnfr.201100440 22058071
256. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Coban D, Milenkovic D, Chanet A, Khallou-Laschet J, Sabbe L, Palagani A, Vanden Berghe W, Mazur A, Morand C, Mol Nutr Food Res 2012 56 1270 1281 10.1002/mnfr.201100818 22753158
257. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW, Proc Natl Acad Sci U S A 2009 106 16764 16769 10.1073/pnas.0909142106 19805370
258. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. Marambaud P, Zhao H, Davies P, J Biol Chem 2005 280 37377 37382 10.1074/jbc.M508246200 16162502
259. Resveratrol acts not through anti-aggregative pathways but mainly via its scavenging properties against Abeta and Abeta-metal complexes toxicity. Granzotto A, Zatta P, PLoS One 2011 6 21565 10.1371/journal.pone.0021565 21738712
260. Resveratrol mitigates lipopolysaccharide- and Abeta-mediated microglial inflammation by inhibiting the TLR4/NF-kappaB/STAT signaling cascade. Capiralla H, Vingtdeux V, Zhao H, Sankowski R, Al-Abed Y, Davies P, Marambaud P, J Neurochem 2012 120 461 472 10.1111/j.1471-4159.2011.07594.x 22118570
261. Resveratrol protects rats from Abeta-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. Huang TC, Lu KT, Wo YY, Wu YJ, Yang YL, PLoS One 2011 6 29102 10.1371/journal.pone.0029102 22220203
262. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE, Neurochem Int 2009 54 111 118 10.1016/j.neuint.2008.10. 008 19041676
263. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. Wang J, Ho L, Zhao Z, Seror I, Humala N, Dickstein DL, Thiyagarajan M, Percival SS, Talcott ST, Pasinetti GM, FASEB J 2006 20 2313 2320 10.1096/fj.06-6281com 17077308
264. Clinical trials of resveratrol. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K, Ann N Y Acad Sci 2011 1215 161 169 10.1111/j.1749-6632. 2010.05853.x 21261655
265. Effect of trans-resveratrol on the thrombogenicity and atherogenicity in apolipoprotein E-deficient and low-density lipoprotein receptor-deficient mice. Fukao H, Ijiri Y, Miura M, Hashimoto M, Yamashita T, Fukunaga C, Oiwa K, Kawai Y, Suwa M, Yamamoto J, Blood Coagul Fibrinolysis 2004 15 441 446 10.1097/00001721-200408000-00001 15311151
266. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, Wierzbicki M, Verbeuren TJ, Cohen RA, Diabetes 2006 55 2180 2191 10.2337/db05-1188 16873680
267. Long-term effects of resveratrol supplementation on suppression of atherogenic lesion formation and cholesterol synthesis in apo E-deficient mice. Do GM, Kwon EY, Kim HJ, Jeon SM, Ha TY, Park T, Choi MS, Biochem Biophys Res Commun 2008 374 55 59 10.1016/j.bbrc.2008.06.113 18611391
268. A dietary mixture containing fish oil, resveratrol, lycopene, catechins, and vitamins E and C reduces atherosclerosis in transgenic mice. Verschuren L, Wielinga PY, van DW, Tijani S, Toet K, van OB, Kooistra T, Kleemann R, J Nutr 2011 141 863 869 10.3945/jn.110.133751 21411607
269. Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM, Int J Mol Med 2005 16 533 540 16142383
270. Inhibitory effects of Polygonum cuspidatum water extract (PCWE) and its component resveratrol [correction of rasveratrol] on acyl-coenzyme A-cholesterol acyltransferase activity for cholesteryl ester synthesis in HepG2 cells. Park CS, Lee YC, Kim JD, Kim HM, Kim CH, Vascul Pharmacol 2004 40 279 284 10.1016/j.vph.2004.01.003 15063831
271. ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Rong JX, Blachford C, Feig JE, Bander I, Mayne J, Kusunoki J, Miller C, Davis M, Wilson M, Dehn S, Thorp E, Tabas I, Taubman MB, Rudel LL, Fisher EA, Arterioscler Thromb Vasc Biol 2013 33 4 12 10.1161/ATVBAHA.112.252056 23139293
272. Manzamine A, a marine-derived alkaloid, inhibits accumulation of cholesterol ester in macrophages and suppresses hyperlipidemia and atherosclerosis in vivo. Eguchi K, Fujiwara Y, Hayashida A, Horlad H, Kato H, Rotinsulu H, Losung F, Mangindaan RE, de Voogd NJ, Takeya M, Tsukamoto S, Bioorg Med Chem 2013 21 3831 3838 10.1016/j.bmc.2013.04.025 23665143
273. Acyl coenzyme A:cholesterol acyltransferase inhibitors as hypolipidemic and antiatherosclerotic drugs. Alegret M, Llaverias G, Silvestre JS, Methods Find Exp Clin Pharmacol 2004 26 563 586 10.1358/mf.2004.26.7.863738 15538545
274. Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide. Puglielli L, Konopka G, Pack-Chung E, Ingano LA, Berezovska O, Hyman BT, Chang TY, Tanzi RE, Kovacs DM, Nat Cell Biol 2001 3 905 912 10.1038/ncb1001-905 11584272
275. Inhibition of acyl-coenzyme A: cholesterol acyl transferase modulates amyloid precursor protein trafficking in the early secretory pathway. Huttunen HJ, Peach C, Bhattacharyya R, Barren C, Pettingell W, Hutter-Paier B, Windisch M, Berezovska O, Kovacs DM, FASEB J 2009 23 3819 3828 10.1096/fj.09-134999 19625658
276. The acyl-coenzyme A: cholesterol acyltransferase inhibitor CI-1011 reverses diffuse brain amyloid pathology in aged amyloid precursor protein transgenic mice. Huttunen HJ, Havas D, Peach C, Barren C, Duller S, Xia W, Frosch MP, Hutter-Paier B, Windisch M, Kovacs DM, J Neuropathol Exp Neurol 2010 69 777 788 10.1097/NEN.0b013e3181e77ed9 20613640
277. Acat1 knockdown gene therapy decreases amyloid-beta in a mouse model of Alzheimer's disease. Murphy SR, Chang CC, Dogbevia G, Bryleva EY, Bowen Z, Hasan MT, Chang TY, Mol Ther 2013 21 1497 1506 10.1038/mt.2013.118 23774792
278. The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model. Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C, Health Technol Assess 2012 16 1 470
279. Acetylcholinesterase inhibitors attenuate atherogenesis in apolipoprotein E-knockout mice. Inanaga K, Ichiki T, Miyazaki R, Takeda K, Hashimoto T, Matsuura H, Sunagawa K, Atherosclerosis 2010 213 52 58 10.1016/j. atherosclerosis.2010.07.027 20723895
280. Protein structure similarity clustering and natural product structure as guiding principles in drug discovery. Koch MA, Waldmann H, Drug Discov Today 2005 10 471 483 10.1016/S1359-6446(05)03419-7 15809193
281. GWAS of butyrylcholinesterase activity identifies four novel loci, independent effects within BCHE and secondary associations with metabolic risk factors. Benyamin B, Middelberg RP, Lind PA, Valle AM, Gordon S, Nyholt DR, Medland SE, Henders AK, Heath AC, Madden PA, Visscher PM, O'Connor DT, Montgomery GW, Martin NG, Whitfield JB, Hum Mol Genet 2011 20 4504 4514 10.1093/hmg/ddr375 21862451
282. APOE and BCHE as modulators of cerebral amyloid deposition: a florbetapir PET genome-wide association study. Ramanan VK, Risacher SL, Nho K, Kim S, Swaminathan S, Shen L, Foroud TM, Hakonarson H, Huentelman MJ, Aisen PS, Petersen RC, Green RC, Jack CR, Koeppe RA, Jagust WJ, Weiner MW, Saykin AJ, Mol Psychiatry 2013 19 351 357 23419831
283. Inhibition of cholinesterase activity by tetrahydroaminoacridine and the hemisuccinate esters of tocopherol and cholesterol. Chelliah J, Smith JD, Fariss MW, Biochim Biophys Acta 1994 1206 17 26 10.1016/0167-4838(94)90067-1 8186246
284. Mind over immunity. Tracey KJ, Czura CJ, Ivanova S, FASEB J 2001 15 1575 1576 10.1096/fj.01-0148hyp 11427490
285. Intracranial atherosclerosis as a contributing factor to Alzheimer's disease dementia. Roher AE, Tyas SL, Maarouf CL, Daugs ID, Kokjohn TA, Emmerling MR, Garami Z, Belohlavek M, Sabbagh MN, Sue LI, Beach TG, Alzheimers Dement 2011 7 436 444 10.1016/j.jalz.2010.08.228 21388893
286. Variations in the transcriptome of Alzheimer's disease reveal molecular networks involved in cardiovascular diseases. Ray M, Ruan J, Zhang W, Genome Biol 2008 9 148 10.1186/gb-2008-9-10-r148 18842138
287. ApoE4 is more efficient than E3 in brain access by herpes simplex virus type 1. Burgos JS, Ramirez C, Sastre I, Bullido MJ, Valdivieso F, Neuroreport 2003 14 1825 1827 10.1097/00001756-200310060-00013 14534428
288. Apolipoprotein E-deficient mice develop an anti-Chlamydophila pneumoniae T helper 2 response and resist vascular infection. Nazzal D, Therville N, Yacoub-Youssef H, Garcia V, Thomsen M, Levade T, Segui B, Benoist H, J Infect Dis 2010 202 782 790 10.1086/655700 20632890
289. Apolipoprotein E-deficient mice have an impaired immune response to Klebsiella pneumoniae. de BN, Netea MG, Demacker PN, Kullberg BJ, van der Meer JW, Stalenhoef AF, Eur J Clin Invest 2000 30 818 822 10.1046/j.1365-2362.2000. 00715.x 10998083
290. Apolipoprotein E-deficient mice have impaired innate immune responses to Listeria monocytogenes in vivo. Roselaar SE, Daugherty A, J Lipid Res 1998 39 1740 1743 9741685
291. Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol. Ghosh J, Das S, Guha R, Ghosh D, Naskar K, Das A, Roy S, J Lipid Res 2012 53 2560 2572 10.1194/jlr.M026914 23060454
292. Effect of apolipoprotein E on the cerebral load of latent herpes simplex virus type 1 DNA. Burgos JS, Ramirez C, Sastre I, Valdivieso F, J Virol 2006 80 5383 5387 10.1128/JVI.00006-06 16699018
293. Influence of low-density lipoprotein (LDL) receptor on lipid composition, inflammation and parasitism during Toxoplasma gondii infection. Portugal LR, Fernandes LR, Pietra Pedroso VS, Santiago HC, Gazzinelli RT, Alvarez-Leite JI, Microbes Infect 2008 10 276 284 10.1016/j.micinf.2007.12.001 18316222
294. Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, Cavrois M, Huang Y, Mahley RW, Dolan MJ, McCune JM, Ahuja SK, Proc Natl Acad Sci U S A 2008 105 8718 8723 10.1073/pnas.0803526105 18562290
295. The load of Chlamydia pneumoniae in the Alzheimer's brain varies with APOE genotype. Gerard HC, Wildt KL, Whittum-Hudson JA, Lai Z, Ager J, Hudson AP, Microb Pathog 2005 39 19 26 10.1016/j.micpath.2005.05.002 15998578
296. Does apolipoprotein E polymorphism influence susceptibility to malaria? Wozniak MA, Faragher EB, Todd JA, Koram KA, Riley EM, Itzhaki RF, J Med Genet 2003 40 348 351 10.1136/jmg.40.5.348 12746397
297. Steroid and sterol 7-hydroxylation: Ancient pathways. Lathe R, Steroids 2002 67 967 977 10.1016/S0039-128X(02)00044-2 12398993
298. Comparison of the intracellular metabolism and trafficking of 25-hydroxycholesterol and cholesterol in macrophages. Morel DW, Edgerton ME, Warner GE, Johnson WJ, Phillips MC, Rothblat GH, J Lipid Res 1996 37 2041 2051 8895069
299. Liver X receptor in cholesterol metabolism. Zhao C, Dahlman-Wright K, J Endocrinol 2010 204 233 240 10.1677/JOE-09-0271 19837721
300. Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ, Proc Natl Acad Sci U S A 1999 96 266 271 10.1073/pnas.96.1.266 9874807
301. 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG, J Biol Chem 2001 276 38378 38387 10.1074/jbc.M105805200 11504730
302. The oxysterol, 27-hydroxycholesterol, links cholesterol metabolism to bone homeostasis through its actions on the estrogen and liver X receptors. Nelson ER, DuSell CD, Wang X, Howe MK, Evans G, Michalek RD, Umetani M, Rathmell JC, Khosla S, Gesty-Palmer D, McDonnell DP, Endocrinology 2011 152 4691 4705 10.1210/en.2011-1298 21933863
303. Selective distribution of oxysterols in atherosclerotic lesions and human plasma lipoproteins. Vaya J, Aviram M, Mahmood S, Hayek T, Grenadir E, Hoffman A, Milo S, Free Radic Res 2001 34 485 497 10.1080/10715760100300431 11378532
304. Oxysterols and atherosclerosis. Brown AJ, Jessup W, Atherosclerosis 1999 142 1 28 10.1016/S0021-9150(98)00196-8 9920502
305. Changes in the levels of cerebral and extracerebral sterols in the brain of patients with Alzheimer's disease. Heverin M, Bogdanovic N, Lutjohann D, Bayer T, Pikuleva I, Bretillon L, Diczfalusy U, Winblad B, Bjorkhem I, J Lipid Res 2004 45 186 193 14523054
306. Marked accumulation of 27-hydroxycholesterol in the brains of Alzheimer's patients with the Swedish APP 670/671 mutation. Shafaati M, Marutle A, Pettersson H, Lovgren-Sandblom A, Olin M, Pikuleva I, Winblad B, Nordberg A, Bjorkhem I, J Lipid Res 2011 52 1004 1010 10.1194/jlr.M014548 21335619
307. Alzheimer's disease: brain desmosterol levels. Wisniewski T, Newman K, Javitt NB, J Alzheimers Dis 2013 33 881 888 23042211
308. Alzheimer's disease: neuroprogesterone, epoxycholesterol, and ABC transporters as determinants of neurodesmosterol tissue levels and its role in amyloid protein processing. Javitt NB, J Alzheimers Dis 2013 35 441 450 23455994
309. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, Lacaze P, Watterson S, Griffiths SJ, Spann NJ, Meljon A, Talbot S, Krishnan K, Covey DF, Wenk MR, Craigon M, Ruzsics Z, Haas J, Angulo A, Griffiths WJ, Glass CK, Wang Y, Ghazal P, Immunity 2013 38 106 118 10.1016/j.immuni.2012.11.004 23273843
310. Still another activity by the highly promiscuous enzyme CYP3A4: 25-hydroxylation of cholesterol. Diczfalusy U, Bjorkhem I, J Lipid Res 2011 52 1447 1449 10.1194/jlr.E017806 21652732
311. 24-, 25- and 27-hydroxylation of cholesterol by a purified preparation of 27-hydroxylase from pig liver. Lund E, Bjorkhem I, Furster C, Wikvall K, Biochim Biophys Acta 1993 1166 177 182 10.1016/0005-2760(93)90094-P 8443234
312. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Lund EG, Guileyardo JM, Russell DW, Proc Natl Acad Sci U S A 1999 96 7238 7243 10.1073/pnas.96.13.7238 10377398
313. cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. Lund EG, Kerr TA, Sakai J, Li WP, Russell DW, J Biol Chem 1998 273 34316 34327 10.1074/jbc.273.51.34316 9852097
314. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, Flaring U, Bjorkbacka H, J Lipid Res 2009 50 2258 2264 10.1194/jlr.M900107-JLR200 19502589
315. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. Park K, Scott AL, J Leukoc Biol 2010 88 1081 1087 10.1189/jlb.0610318 20699362
316. Cholesterol ester formation in cultured human fibroblasts. Stimulation by oxygenated sterols. Brown MS, Dana SE, Goldstein JL, J Biol Chem 1975 250 4025 4027 1126942
317. Activation of acyl-coenzyme A: cholesterol acyltransferase by cholesterol or by oxysterol in a cell-free system. Cheng D, Chang CC, Qu X, Chang TY, J Biol Chem 1995 270 685 695 10.1074/jbc.270.2.685 7822296
318. ATF3 protects against atherosclerosis by suppressing 25- hydroxycholesterol-induced lipid body formation. Gold ES, Ramsey SA, Sartain MJ, Selinummi J, Podolsky I, Rodriguez DJ, Moritz RL, Aderem A, J Exp Med 2012 209 807 817 10.1084/jem.20111202 22473958
319. 25-Hydroxycholesterol regulates cholesterol homeostasis in the murine CATH.a neuronal cell line. Waltl S, Patankar JV, Fauler G, Nusshold C, Ullen A, Eibinger G, Wintersperger A, Kratky D, Malle E, Sattler W, Neurosci Lett 2013 539 16 21 23347841
320. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, Freiberg AN, Su L, Lee B, Cheng G, Immunity 2013 38 92 105 10.1016/j.immuni.2012.11.005 23273844
321. 25-Hydroxycholesterol activates the integrated stress response to reprogram transcription and translation in macrophages. Shibata N, Carlin AF, Spann NJ, Saijo K, Morello CS, McDonald JG, Romanoski CE, Maurya MR, Kaikkonen MU, Lam MT, Crotti A, Reichart D, Fox JN, Quehenberger O, Raetz CR, Sullards MC, Murphy RC, Merrill AH Jr, Brown HA, Dennis EA, Fahy E, Subramaniam S, Cavener DR, Spector DH, Russell DW, Glass CK, J Biol Chem 2013 288 35812 35823 10.1074/jbc.M113.519637 24189069
322. Oxysterols direct immune cell migration via EBI2. Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, Guerini D, Baumgarten BU, Roggo S, Wen B, Knochenmuss R, Noel S, Gessier F, Kelly LM, Vanek M, Laurent S, Preuss I, Miault C, Christen I, Karuna R, Li W, Koo DI, Suply T, Schmedt C, Peters EC, Falchetto R, Katopodis A, Spanka C, Roy MO, Detheux M, et al. Nature 2011 475 524 527 10.1038/nature10280 21796212
323. On the formation and possible biological role of 25-hydroxycholesterol. Diczfalusy U, Biochimie 2013 95 455 460 10.1016/j.biochi.2012.06.016 22732193
324. Neurosteroid hydroxylase CYP7B: vivid reporter activity in dentate gyrus of gene-targeted mice and abolition of a widespread pathway of steroid and oxysterol hydroxylation. Rose K, Allan A, Gauldie S, Stapleton G, Dobbie L, Dott K, Martin C, Wang L, Hedlund E, Seckl JR, Gustafsson JA, Lathe R, J Biol Chem 2001 276 23937 23944 10.1074/jbc.M011564200 11290741
325. Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. Yi T, Wang X, Kelly LM, An J, Xu Y, Sailer AW, Gustafsson JA, Russell DW, Cyster JG, Immunity 2012 37 535 548 10.1016/j.immuni.2012.06.015 22999953
326. Purification of oxysterol binding protein from hamster liver cytosol. Dawson PA, van der Westhuyzen DR, Goldstein JL, Brown MS, J Biol Chem 1989 264 9046 9052 2722817
327. Natural products reveal cancer cell dependence on oxysterol-binding proteins. Burgett AW, Poulsen TB, Wangkanont K, Anderson DR, Kikuchi C, Shimada K, Okubo S, Fortner KC, Mimaki Y, Kuroda M, Murphy JP, Schwalb DJ, Petrella EC, Cornella-Taracido I, Schirle M, Tallarico JA, Shair MD, Nat Chem Biol 2011 7 639 647 10.1038/nchembio.625 21822274
328. Translocation of oxysterol binding protein to Golgi apparatus triggered by ligand binding. Ridgway ND, Dawson PA, Ho YK, Brown MS, Goldstein JL, J Cell Biol 1992 116 307 319 10.1083/jcb.116.2.307 1730758
329. Multisite phosphorylation of oxysterol-binding protein regulates sterol binding and activation of sphingomyelin synthesis. Goto A, Liu X, Robinson CA, Ridgway ND, Mol Biol Cell 2012 23 3624 3635 10.1091/mbc.E12-04-0283 22875984
330. Oxysterol-binding protein-1 (OSBP1) modulates processing and trafficking of the amyloid precursor protein. Zerbinatti CV, Cordy JM, Chen CD, Guillily M, Suon S, Ray WJ, Seabrook GR, Abraham CR, Wolozin B, Mol Neurodegener 2008 3 5 10.1186/1750-1326-3-5 18348724
331. Expression of human OSBP-related protein 1 L in macrophages enhances atherosclerotic lesion development in LDL receptor-deficient mice. Yan D, Jauhiainen M, Hildebrand RB, van Willems DK, van Berkel TJ, Ehnholm C, Van EM, Olkkonen VM, Arterioscler Thromb Vasc Biol 2007 27 1618 1624 10.1161/ATVBAHA.107.144121 17478758
332. Macrophage oxysterols and their binding proteins: roles in atherosclerosis. Olkkonen VM, Curr Opin Lipidol 2012 23 462 470 10.1097/MOL.0b013e328356dba0 22814702
333. The cholesterol metabolite 25-hydroxycholesterol activates estrogen receptor alpha-mediated signaling in cancer cells and in cardiomyocytes. Lappano R, Recchia AG, de Francesco EM, Angelone T, Cerra MC, Picard D, Maggiolini M, PLoS One 2011 6 16631 10.1371/journal.pone.0016631 21304949
334. Proteome-wide mapping of cholesterol-interacting proteins in mammalian cells. Hulce JJ, Cognetta AB, Niphakis MJ, Tully SE, Cravatt BF, Nat Methods 2013 10 259 264 10.1038/nmeth.2368 23396283
335. A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease. Coronary Artery Disease (C4D) Genetics Consortium, Nat Genet 2011 43 339 344 10.1038/ng.782 21378988
336. Large-scale gene-centric analysis identifies novel variants for coronary artery disease. IBC 50K CAD Consortium, PLoS Genet 2011 7 1002260 10.1371/journal.pgen.1002260 21966275
337. Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease. Papassotiropoulos A, Lambert JC, Wavrant-De Vrieze F, Wollmer MA, von der KH, Streffer JR, Maddalena A, Huynh KD, Wolleb S, Lutjohann D, Schneider B, Thal DR, Grimaldi LM, Tsolaki M, Kapaki E, Ravid R, Konietzko U, Hegi T, Pasch T, Jung H, Braak H, Amouyel P, Rogaev EI, Hardy J, Hock C, Nitsch RM, Neurodegener Dis 2005 2 233 241 10.1159/000090362 16909003
338. Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. Laumet G, Chouraki V, Grenier-Boley B, Legry V, Heath S, Zelenika D, Fievet N, Hannequin D, Delepine M, Pasquier F, Hanon O, Brice A, Epelbaum J, Berr C, Dartigues JF, Tzourio C, Campion D, Lathrop M, Bertram L, Amouyel P, Lambert JC, J Alzheimers Dis 2010 20 1181 1188 20413850
339. Genomics and proteomics of vertebrate cholesterol ester lipase (LIPA) and cholesterol 25-hydroxylase (CH25H). Holmes RS, Vandeberg JL, Cox LA, 3 Biotech 2011 1 99 109 22582164
340. Lysosomal acid lipase and atherosclerosis. Du H, Grabowski GA, Curr Opin Lipidol 2004 15 539 544 10.1097/00041433-200410000-00007 15361789
341. Increased 25-hydroxycholesterol concentrations in the lungs of patients with chronic obstructive pulmonary disease. Sugiura H, Koarai A, Ichikawa T, Minakata Y, Matsunaga K, Hirano T, Akamatsu K, Yanagisawa S, Furusawa M, Uno Y, Yamasaki M, Satomi Y, Ichinose M, Respirology 2012 17 533 540 10.1111/j.1440-1843.2012.02136.x 22295989
342. Chronic bronchial infection in COPD. Is there an infective phenotype? Matkovic Z, Miravitlles M, Respir Med 2013 107 10 22 10.1016/j.rmed.2012.10.024 23218452
343. Cholesterol is superior to 7-ketocholesterol or 7 alpha- hydroxycholesterol as an allosteric activator for acyl-coenzyme A:cholesterol acyltransferase 1. Zhang Y, Yu C, Liu J, Spencer TA, Chang CC, Chang TY, J Biol Chem 2003 278 11642 11647 10.1074/jbc.M211559200 12533546
344. Regulation of cholesterol biosynthesis and esterification by 25-hydroxycholesterol in a macrophage-like cell line: uncoupling by progesterone. Miller SC, Melnykovych G, J Lipid Res 1984 25 991 999 6491542
345. Neuronal cholesterol esterification by ACAT1 in Alzheimer's disease. Chang TY, Chang CC, Bryleva E, Rogers MA, Murphy SR, IUBMB Life 2010 62 261 267 20101629
346. Regulation of endoplasmic reticulum cholesterol by plasma membrane cholesterol. Lange Y, Ye J, Rigney M, Steck TL, J Lipid Res 1999 40 2264 2270 10588952
347. Inhibition of acyl-coenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytes. An S, Jang YS, Park JS, Kwon BM, Paik YK, Jeong TS, Exp Mol Med 2008 40 407 417 10.3858/emm.2008.40.4.407 18779653
348. Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K, Brain Res Mol Brain Res 2003 110 119 125 10.1016/S0169-328X(02) 00647-2 12573540
349. Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. Nelson TJ, Alkon DL, J Biol Chem 2005 280 7377 7387 10.1074/jbc.M409071200 15591071
350. Oxidation of cholesterol catalyzed by amyloid beta-peptide (Abeta)-Cu complex on lipid membrane. Yoshimoto N, Tasaki M, Shimanouchi T, Umakoshi H, Kuboi R, J Biosci Bioeng 2005 100 455 459 10.1263/jbb.100.455 16310737
351. Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. Puglielli L, Friedlich AL, Setchell KD, Nagano S, Opazo C, Cherny RA, Cherny RA, Barnham KJ, Wade JD, Melov S, Kovacs DM, Bush AI, J Clin Invest 2005 115 2556 2563 10.1172/JCI23610 16127459
352. Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ, Castellani RJ, Crain BJ, Davies P, Del TK, Duyckaerts C, Frosch MP, Haroutunian V, Hof PR, Hulette CM, Hyman BT, Iwatsubo T, Jellinger KA, Jicha GA, Kovari E, Kukull WA, Leverenz JB, Love S, Mackenzie IR, Mann DM, Masliah E, McKee AC, Montine TJ, Morris JC, Schneider JA, et al. J Neuropathol Exp Neurol 2012 71 362 381 10.1097/NEN.0b013e31825018f7 22487856
353. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD, PLoS One 2010 5 9505 10.1371/journal.pone.0009505 20209079
354. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH, JAMA 2009 302 2557 2564 10.1001/jama.2009.1866 20009055
355. The immune system, amyloid-beta peptide, and Alzheimer's disease. Weksler ME, Gouras G, Relkin NR, Szabo P, Immunol Rev 2005 205 244 256 10.1111/j.0105-2896.2005.00264.x 15882358
356. The evolution of Alzheimer disease, the reproductive schedule, and apoE isoforms. Finch CE, Sapolsky RM, Neurobiol Aging 1999 20 407 428 10.1016/S0197-4580(99)00053-6 10604433
357. Sickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Ashley-Koch A, Yang Q, Olney RS, Am J Epidemiol 2000 151 839 845 10.1093/oxfordjournals.aje.a010288 10791557
358. Rediscovery of cerebrosterol. Bjorkhem I, Lipids 2007 42 5 14 10.1007/s11745-006-1003-2 17393206
359. Distribution of cholesterol 24-hydroxylase in the monkey brain. He X, Ong WY, Hua Q, Neurosci Bull 2010 26 197 204 10.1007/s12264-010-1224-5 20502497
360. Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Kolsch H, Lutjohann D, Ludwig M, Schulte A, Ptok U, Jessen F, von BK, Rao ML, Maier W, Heun R, Mol Psychiatry 2002 7 899 902 10.1038/sj.mp.4001109 12232784
361. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease. Strittmatter WJ, Saunders AM, Goedert M, Weisgraber KH, Dong LM, Jakes R, Huang DY, Pericak-Vance M, Schmechel D, Roses AD, Proc Natl Acad Sci U S A 1994 91 11183 11186 10.1073/pnas.91.23.11183 7972031
362. Herpesvirus latency confers symbiotic protection from bacterial infection. Barton ES, White DW, Cathelyn JS, Brett-McClellan KA, Engle M, Diamond MS, Miller VL, Virgin HW, Nature 2007 447 326 329 10.1038/nature05762 17507983
363. Impaired cholesterol efflux in senescent macrophages promotes age-related macular degeneration. Sene A, Khan AA, Cox D, Nakamura RE, Santeford A, Kim BM, Sidhu R, Onken MD, Harbour JW, Hagbi-Levi S, Chowers I, Edwards PA, Baldan A, Parks JS, Ory DS, Apte RS, Cell Metab 2013 17 549 561 10.1016/j.cmet.2013.03.009 23562078
364. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Conboy IM, Conboy MJ, Wagers AJ, Girma ER, Weissman IL, Rando TA, Nature 2005 433 760 764 10.1038/nature03260 15716955